Cargando…

A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis

Background: Locally acting, well-tolerated treatments for systemic sclerosis (SSc) digital ulcers (DUs) are needed. Objectives: Our primary aim was to investigate the safety, feasibility, and tolerability of a novel low-level light therapy (LTTT). A secondary aim was to tentatively assess efficacy....

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, M., Moore, T., Manning, J., Wilkinson, J., Watson, S., Samraj, P., Dinsdale, G., Roberts, C., Rhodes, L. E., Herrick, A. L., Murray, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484448/
https://www.ncbi.nlm.nih.gov/pubmed/29862855
http://dx.doi.org/10.1080/09546634.2018.1484875
_version_ 1783414117442256896
author Hughes, M.
Moore, T.
Manning, J.
Wilkinson, J.
Watson, S.
Samraj, P.
Dinsdale, G.
Roberts, C.
Rhodes, L. E.
Herrick, A. L.
Murray, A.
author_facet Hughes, M.
Moore, T.
Manning, J.
Wilkinson, J.
Watson, S.
Samraj, P.
Dinsdale, G.
Roberts, C.
Rhodes, L. E.
Herrick, A. L.
Murray, A.
author_sort Hughes, M.
collection PubMed
description Background: Locally acting, well-tolerated treatments for systemic sclerosis (SSc) digital ulcers (DUs) are needed. Objectives: Our primary aim was to investigate the safety, feasibility, and tolerability of a novel low-level light therapy (LTTT). A secondary aim was to tentatively assess efficacy. Methods: A custom-built device comprising infrared (850 nm), red (660 nm), and violet (405 nm) LEDs was utilized. DUs were irradiated with 10 J/cm(2) twice weekly for 3 weeks, with follow-up at weeks 4 and 8. Any safety concerns were documented. Patient opinion on time to deliver, feasibility, and pain visual analogue score (VAS; 0–100, 100 most severe) was collected. Patient and clinician DU global assessment VAS were documented. DUs were evaluated by laser Doppler perfusion imaging pre- and post-irradiation. Results: In all, 14 DUs in eight patients received a total of 46 light exposures, with no safety concerns. All patients considered LTTT ‘took just the right amount of time’ and was ‘feasible’, with a low associated mean pain VAS of 1.6 (SD: 5.2). Patient and clinician global DC VAS improved during the study (mean change: –7.1 and –5.2, respectively, both p < .001). DU perfusion significantly increased post-irradiation. Conclusions: LTTT for DUs is safe, feasible, and well tolerated. There was an early tentative suggestion of treatment efficacy.
format Online
Article
Text
id pubmed-6484448
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-64844482019-05-10 A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis Hughes, M. Moore, T. Manning, J. Wilkinson, J. Watson, S. Samraj, P. Dinsdale, G. Roberts, C. Rhodes, L. E. Herrick, A. L. Murray, A. J Dermatolog Treat Complex Medical Dermatology Background: Locally acting, well-tolerated treatments for systemic sclerosis (SSc) digital ulcers (DUs) are needed. Objectives: Our primary aim was to investigate the safety, feasibility, and tolerability of a novel low-level light therapy (LTTT). A secondary aim was to tentatively assess efficacy. Methods: A custom-built device comprising infrared (850 nm), red (660 nm), and violet (405 nm) LEDs was utilized. DUs were irradiated with 10 J/cm(2) twice weekly for 3 weeks, with follow-up at weeks 4 and 8. Any safety concerns were documented. Patient opinion on time to deliver, feasibility, and pain visual analogue score (VAS; 0–100, 100 most severe) was collected. Patient and clinician DU global assessment VAS were documented. DUs were evaluated by laser Doppler perfusion imaging pre- and post-irradiation. Results: In all, 14 DUs in eight patients received a total of 46 light exposures, with no safety concerns. All patients considered LTTT ‘took just the right amount of time’ and was ‘feasible’, with a low associated mean pain VAS of 1.6 (SD: 5.2). Patient and clinician global DC VAS improved during the study (mean change: –7.1 and –5.2, respectively, both p < .001). DU perfusion significantly increased post-irradiation. Conclusions: LTTT for DUs is safe, feasible, and well tolerated. There was an early tentative suggestion of treatment efficacy. Taylor & Francis 2018-07-31 /pmc/articles/PMC6484448/ /pubmed/29862855 http://dx.doi.org/10.1080/09546634.2018.1484875 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Complex Medical Dermatology
Hughes, M.
Moore, T.
Manning, J.
Wilkinson, J.
Watson, S.
Samraj, P.
Dinsdale, G.
Roberts, C.
Rhodes, L. E.
Herrick, A. L.
Murray, A.
A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis
title A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis
title_full A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis
title_fullStr A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis
title_full_unstemmed A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis
title_short A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis
title_sort feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis
topic Complex Medical Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484448/
https://www.ncbi.nlm.nih.gov/pubmed/29862855
http://dx.doi.org/10.1080/09546634.2018.1484875
work_keys_str_mv AT hughesm afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT mooret afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT manningj afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT wilkinsonj afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT watsons afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT samrajp afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT dinsdaleg afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT robertsc afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT rhodesle afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT herrickal afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT murraya afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT hughesm feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT mooret feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT manningj feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT wilkinsonj feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT watsons feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT samrajp feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT dinsdaleg feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT robertsc feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT rhodesle feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT herrickal feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis
AT murraya feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis